Bayer

A surprise outlook upgrade hailed by the markets

01/08/25 -"Before its detailed Q2 25 results, Bayer upgraded its 2025 outlook, backed by a better-than-expected performance in the Pharmaceuticals segment. Even the Q2 adjusted EBITDA was materially ahead of ..."

PDF page sample
Pages
79
Language
English
Published on
01/08/25
Download
You may also be interested by these reports :
04/08/25
Apart from revising down our earnings forecasts, and our DCF and NAV valuations, we have also reduced the premium on the peer-based valuation to 10% ...
04/08/25
BioNTech’s Q2 sales fell short of market expectations. However, the narrower operating loss compared to analysts’ estimates was well received by the ...
01/08/25
Before its detailed Q2 25 results, Bayer upgraded its 2025 outlook, backed by a better-than-expected performance in the Pharmaceuticals segment. Even ...
31/07/25
The H1 results materially exceeded expectations, driven by Bimzelx and other key immunology/neurology medicines. Consequently, the management ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO